dr opat on the accessibility of sonrotoclax plus zanubrutinib in r/r cll/sll
Published 2 months ago • 33 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
9:49
sonrotoclax plus zanubrutinib shows deep response in cll
-
2:36
sonrotoclax plus zanubrutinib combination shows promise in treatment-naïve cll/sll
-
46:18
eha 2024 - updates on cll with dr. banerji, dr. assouline, and dr. hillis
-
4:05
bcl2 and btk dual-inhibition with sonrotoclax zanubrutinib in previously untreated cll and sll
-
12:05
sonrotoclax plus zanubrutinib for cll: recruiting clinical trial
-
1:38
results from a study on the combination of sonrotoclax and zanubrutinib in r/r mcl
-
1:18
celestial-tncll: ongoing phase iii study of sonrotoclax zanubrutinib vs ven obi for tn cll
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
16:14
clinical clip from eha 2024
-
1:03
zanubrutinib plus venetoclax for patients with cll
-
2:37
second generation cll treatment: zanubrutinib sonrotoclax | constantine tam, md, mbbs | ash 2023
-
3:36
sequoia trial: zanubrutinib venetoclax in treatment-naïve patients with cll/sll
-
2:11
preliminary results from arm d of the sequoia study: zanubrutinib plus venetoclax in cll
-
0:58
what is your preferred btk inhibitor in cll?
-
2:26
the value of zanubrutinib in the cll treatment armamentarium & sequoia trial updates
-
2:04
updated long-term follow-up of sequoia: zanubrutinib vs bendamustine-rituximab in untreated cll/sll
-
1:03
maic of zanubrutinib and venetoclax ibrutinib in treatment-naïve cll
-
46:14
cll: key take-home messages from eha and asco 2024